<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601274</url>
  </required_header>
  <id_info>
    <org_study_id>2014-309-00CH1</org_study_id>
    <nct_id>NCT02601274</nct_id>
  </id_info>
  <brief_title>Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor</brief_title>
  <acronym>HMPL-309</acronym>
  <official_title>Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309,Xiliertinib) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, open-label, multicenter dose-escalation study to assess the safety, tolerability,&#xD;
      pharmacokinetics and preliminary anti-tumor activity of hmpl-309 in patients with advanced&#xD;
      solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two stages to this study: a dose-escalation stage and a dose-expansion stage.&#xD;
&#xD;
      Dose-escalation stage: hmpl-309 administered orally once every day(QD) to patients with&#xD;
      locally advanced or metastatic solid tumors for whom standard therapy either does not exist&#xD;
      or has proven to be ineffective or intolerable. Dose-expansion stage: hmpl-309 administered&#xD;
      orally 300mg once every day(QD) to patients which is only for patients with EGFR positive&#xD;
      oesophageal carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the change of clinical development plan&#xD;
  </why_stopped>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of all types/grades of adverse events</measure>
    <time_frame>from first patient in till 30 days after the last patient last visit</time_frame>
    <description>for each patient, adverse events are collected from the date of consent until 30 days after trial discontinuation</description>
  </primary_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 1-3 Single Dose and Day 1-28 Steady State</time_frame>
    <description>Based on single-dose PK result, multi-dose stage subjects take HMPL-309 once a day or twice a day, PK samples are collected of a single oral dose of HMPL-309 on Day 1 to Day 3. At multiple-dose, Pharmacokinetics(PK) sampling will include a pre-dose and at the 0.5,2,4,6,8 hour time points on days 1,15,21of dosing in the first 21-Day cycle of therapy, and pre-dose on days 2,8,16,and 22 of the first 21-Day cycle of therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1-3 Single Dose and Day 1-28 Steady State</time_frame>
    <description>Based on single-dose PK result, multi-dose stage subjects take HMPL-309 once a day or twice a day, PK samples are collected of a single oral dose of HMPL-309 on Day 1 to Day 3. At multiple-dose, Pharmacokinetics(PK) sampling will include a pre-dose and at the 0.5,2,4,6,8 hour time points on days 1,15,21of dosing in the first 21-Day cycle of therapy, and pre-dose on days 2,8,16,and 22 of the first 21-Day cycle of therapy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Single Group Assignment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 7 dose cohorts,including120mg/160mg/200mg/220mg/300mg/400mg/500mg, QD in the dose escalation stage .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theliatinib</intervention_name>
    <description>Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily</description>
    <arm_group_label>Single Group Assignment</arm_group_label>
    <other_name>HMPL-309,xiliertinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathology confirmed solid tumors&#xD;
&#xD;
          -  Failed to standard treatment or no standard treatments for uncontrolled, recurrent&#xD;
             and/or metastatic advance tumor (whatever previous surgery conditions)&#xD;
&#xD;
        Dose-escalation stage:&#xD;
&#xD;
        &lt;300mg/day cohort no requiremnet for pathological pattern &gt;300mg/day cohort required NCSLC,&#xD;
        head and net squamous carcinoma, or oesophageal carcinoma Dose-expansion stage required&#xD;
        oesophageal carcinoma&#xD;
&#xD;
          -  Age 18-75&#xD;
&#xD;
          -  performance status of 0, or 1, and no worse within 7days&#xD;
&#xD;
          -  Life expected &gt;3 months&#xD;
&#xD;
          -  written informed consent form voluntarily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lab testing within 1 week before enrolled, hemoglobin &lt;9 g/dL or , platelet count &lt;&#xD;
             750,000/mm3 and&lt;150000/mm3,&#xD;
&#xD;
          -  Total bilirubin≥1.5× the upper limit of normal,&#xD;
&#xD;
          -  Serum creatinine higher than normal range&#xD;
&#xD;
          -  Diastolic pressure≥150mmHg or systolic pressure≥100mmHg whatever anti-hypertension&#xD;
             drug used,&#xD;
&#xD;
          -  Serum potassium (whenever potassium implemented) , serum calcium(ionic or albumin-type&#xD;
             calcium) or serum magnesium outside normal ranges(whenever implemented)&#xD;
&#xD;
          -  Within previous 4 weeks treated by systemic anti-tumor therapy, or radiotherapy,&#xD;
             immune therapy, biological or hormonal therapy, and clinical trials. But exclude the&#xD;
             below therapy, Prostate cancer treated by hormonal therapy such as&#xD;
             GnRH(gonadotropin-releasing hormone) analogue or antagonist Hormone replacement&#xD;
             therapy or oral contraceptive Palliative radiotherapy for bone metastasis within 2&#xD;
             weeks&#xD;
&#xD;
          -  Prior documental evidence of resistance to EGFR-TKI (epidermal growth factor&#xD;
             receptor-tyrosine kinase inhibitors)&#xD;
&#xD;
          -  Unrecovered from any previous therapy related toxicity to≤ CTCAE(Common Toxicity&#xD;
             Criteria for Adverse Effects) 0 or 1or unrecovered from any previous surgery&#xD;
&#xD;
          -  Any CNS(central nervous system) metastasis with uncontrolled symptoms&#xD;
&#xD;
          -  Known dysphagia or drug malabsorption&#xD;
&#xD;
          -  Active infections such as acute pneumonia, hepatitis B active period&#xD;
&#xD;
          -  APTT (activated partial thromboplastin time) and/or INR(international normalized&#xD;
             ratio), PT≥2 the upper limit of normal(not including patients treated by&#xD;
             anticoagulation treatment)&#xD;
&#xD;
          -  ocular surface diseases or dry eye syndrome&#xD;
&#xD;
          -  skin disease with obvious symptoms and signs&#xD;
&#xD;
          -  significant cardiovascular disease, including II-IV atrioventricular block, acute&#xD;
             myocardial infarction within 6 months, significant angina or Coronary artery bypass&#xD;
             graft&#xD;
&#xD;
          -  Known existing interstitial lung disease&#xD;
&#xD;
          -  Female patients who are pregnant or feeding, or childbearing potential patient with&#xD;
             pregnant testing positive&#xD;
&#xD;
          -  Any abnormal of clinical and laboratory so that patients unsuitable to attend the&#xD;
             trial sine in the opinion of the investigator&#xD;
&#xD;
          -  Patients unable to comply with the protocol since significant psychological or&#xD;
             psychogenic abnormal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun-Yat-sen univercity cancer centre</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

